Roots Analysis

AUGUST 12, 2024

These diagnostic solutions are essential for detecting and monitoring diseases, identifying genetic abnormalities, and guiding personalized treatment plans. Molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicine.

Genetics 40

Genetics Gene Expression RNA DNA 40

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol is a biotech company that has supplied the global market with reagents for research and medical diagnostics for over 30 years. To support customers performing human genotyping, TIB Molbiol provides custom made LightSNiP assays for SNP analysis. The majority of assays are used to test for infectious diseases.

Genotype 52

Genotype Reagent Genetics Research 52

XTalks

DECEMBER 12, 2023

The worldwide market for neurology clinical trials stood at a valuation of $5.24 Moreover, combining biofluid analytes with molecular pathology (genetic biomarkers) allows for the classification and differentiation of neurodegenerative diseases. billion in 2022. It’s projected to grow at a compound annual growth rate (CAGR) of 5.6

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

Roots Analysis

AUGUST 31, 2023

Quantitative real time polymerase chain reaction ( RT PCR ) and DNA microarray technologies have been successfully used to evaluate the interactions between genes and diet, which is measured in terms of changes in the genetic expression. It is worth mentioning that more than 50 genes in a human body are associated with obesity.

Genome 40

Genome Genomics Genetics Gene 40

The Pharma Data

MARCH 16, 2022

3, and Delta ([link] About TIB Molbiol TIB Molbiol is a subsidiary of Roche Diagnostics that has supplied the global market with reagents for research and medical diagnostics for over 30 years. To support customers performing human genotyping, TIB Molbiol provides custom-made LightSNiP assays for SNP analysis.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

NOVEMBER 24, 2020

PH1 is an ultra-rare genetic disease characterized by oxalate overproduction. On November 19, the European Commission granted marketing authorization for Oxlumo for the treatment of PH1 in all age groups, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

FDA Approval 52

FDA Approval Production RNA Medicine 52

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Medpace’s work contributed to two gene therapies that gained marketing authorization approval in 2022. Rare diseases can often be progressive, chronic and fatal. How Can Study Protocols Be More Effective?

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

Delveinsight

DECEMBER 16, 2020

As per the WHO, more than 100 types of HPV are found worldwide, out of them at least 13 known HPV genotypes can cause cancer of the cervix. A number of antiretroviral drugs are available in the market today, that can be combined in different ways. Trichomoniasis. What are the challenges in sexually transmitted diseases management?

Bacteria 52

Bacteria Development Genotype Vaccine 52